Trial · NCT01362348
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Central Retinal Lesion Thickness (CRT) as Measured by Optical Coherence Tomography (OCT) at Day 29 | Baseline (Week 0) and Day 29 | The Intent-to-treat (ITT) Population comprised of any participant who received at least one dose of study medication. Only those participants with data available at the indicated time point were analyzed. OC dataset was used for analysis. | Microns | MEAN |
| PRIMARY | Change From Baseline in Best Correct Visual Acuity (BCVA) as Measured by the Number of Letters Determined by Electronic Early Treatment Diabetic Retinopathy [ETDRS] Study Visual Acuity (EVA) at Day 29 | Baseline (Day -3 to -1) and Day 29 | ITT Population. Only those participants with data available at the indicated time point were analyzed. OC dataset was used for analysis. | Count of letters | MEAN |
| SECONDARY | Change From Baseline in Central Retinal Lesion Thickness (CRLT) Over Time | Baseline (Week -3 to -1) Up to Follow-up (Day 102) | ITT Population. Only those participants available at the specified time points were analyzed. OC dataset was used for analysis. | Microns | MEAN |
| SECONDARY | Change From Baseline in Intraretinal (IR) or Subretinal (SR) Fluid Thickness, Intraretinal Cysts or Serous Retinal Pigment Epithelial Detachment (PED Thickness) Over Time | Baseline (Week -3 to -1) Up to Follow-up (Day 102) | ITT Population. Only those participants available at the specified time points were analyzed. OC dataset was used for analysis. | Microns | MEAN |
| SECONDARY | Change From Baseline in BCVA Over Time | Baseline (Week -3 to -1) Up to Follow-up (Day 102) | ITT Population. Only those participants available at the specified time points were analyzed. OC dataset was used for analysis. | Letters | MEAN |
| SECONDARY | Change From Baseline in the Area of Choroidal Neovascular (CNV) Size and CNV Total Lesion Complex Size as Measured by Fluorescein Angiography (FA) at Day 29 | Baseline (Day -3 to -1) and Day 29 | ITT Population. Only those participants with data available at the indicated time point were analyzed. OC dataset was used for analysis. | millimeter square | MEAN |
| SECONDARY | Number of Participants With Change in Charactertsics (Atrophy, Pigment, SR Hemorrhage, IR Hemorrhage, SR Fluid and Fibrosis) as Measured by FP | Day 29 | ITT Population. Only those participants with data available at the indicated time point were analyzed. OC dataset was used for analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Who Received Rescue Medication | Up to follow-up (Day 102) | Safety Population comprised of any participant who received at least one dose of study medication. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Ocular Adverse Events (AEs), Non-ocular AEs, Serious Ocular AEs and Serious Non-ocular AEs | Until Follow-up (Day 102) | Safety Population. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Values of Potential Clinical Concern for Ocular Assessments on General Ophthalmic Examination | Up to Follow-up (Day 102) | Safety Population. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Vital Sign Data of Potential Clinical Concern | Up to Follow-up (Day 102) | Safety Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Clinical Chemistry and Hematology Data of Potential Clinical Concern | Up to Follow-up (Day 102) | Safety population. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Abnormal Urinalysis Data by Urine Microscopy and Dipstick Analysis | Up to Follow-up (Day 102) | Safety Population. Only those participants available at the specified time points were analyzed, | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Summary of Plasma Pazonib Concentration | Up to Week 12 | Pharmacokinetic Population was defined as participants in the ITT Population for whom a pharmacokinetic sample was obtained and analyzed. Only those participants available at the specified time points were analyzed. | nanograms per milliliter | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01362348/outcomes